55 mins ago | fiercepharma.com
Johnson & Johnson's ( $JNJ ) Zytiga is FDA-approved for men with advanced prostate cancer . But a new study suggests it may be effective in early-stage disease, too. The small trial--it involved only 58 patients with localized,...
Read more...
Tracy Staton Zytiga J&J prostate cancer tumor neoadjuvant Taplin
2 hrs ago | finance.yahoo.com
Dendreon (DNDN) is retreating after it became known that the SEC is investigating the company. Also weighing on the shares is a successful trial of Johnson & Johnson's (JNJ) drug, Zytiga, which is seen ...
Read more...
Dendreon SEC probe Provenge competitor prostate lawsuit Zytiga cancer JNJ Johnson&Johnson
3 hrs ago | finance.yahoo.com
LYON, France -- EDAP TMS SA , a global leader in therapeutic ultrasound, announced today that its Ablatherm(R) High Intensity Focused Ultrasound (HIFU) will be featured in two presentations supporting ...
Read more...
EDAP HIFU Ablatherm-HIFU prostate localized Ultrasound Intensity TURP Focused treatment cancer TMS Sonolith ESWL
3 hrs ago | eurekalert.org
The American Society of Clinical Oncology today highlighted five studies in a press briefing from among more than 4,500 abstracts publicly posted online at abstract.asco.org in advance of ASCO's 47th Annual Meeting.
Read more...
ASCO cancer study Cancer.Net prostate tumor Meeting annual treatment abiraterone drug crizotinib BRAF
4 hrs ago | news-gazette.com
URBANA — There are few things more grim for a dog than prostate cancer. And when a little scrap of a dog named Bear was diagnosed with this disease in November 2010, nobody figured he'd live longer than six to nine months. But...
Read more...
Debra Pressey Bear Kappert Kapperts dog Schmit UI cancer treatment defy Lisa odds Phillips
4 hrs ago | newsmaxhealth.com
Johnson & Johnson's Zytiga, approved last year to treat metastatic prostate cancer, helped eliminate tumors in high-risk patients whose malignancy hadn’t yet spread, a small study found. The pill was given as an initial therapy...
Read more...
All similar articles: 55 >>
prostate Zytiga cancer Taplin drug patient gland androgen study tumor Biegelsen high-risk
4 hrs ago | streetinsider.com
FREE Breaking News Alerts from StreetInsider.com! Multiple Studies Relating to HIFU and Focal Therapy Being Presented at AUA Demonstrate Growing Interest in the Potential of the Minimally Invasive Treatment to Balance...
Read more...
HIFU prostate AUA cancer ultrasound treatment Sonablate focal US
4 hrs ago | finanznachrichten.de
Novel Triple Mechanism of Action Highlighted Galeterone Demonstrated Promising Efficacy and Was Well-Tolerated with No Dose Limiting Toxicities Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new...
Read more...
galeterone Tokai CRPC prostate androgen receptor TOK-001 Pharmaceuticals Phase cancer mechanism
6 hrs ago | seekingalpha.com
By Theodore Cohen: On Wednesday, May 16, Dendreon Corporation ( DNDN ) announced four presentations to be given at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, taking place June 1-5, 2012 in...
Read more...
Theodore Cohen PSA Provenge Dendreon Sipuleucel-T 22.1 median Genitourinary survival Cancer Baseline Prostate Poster abstract Session 512-patient CT 8:00 Neoadjuvant 12:00
8 hrs ago | thespec.com
Rhonda Birse Rhonda Birse is a breast cancer survivor. Cathie Coward/The Hamilton Spectator Breast and lung cancer survival rates in Hamilton and surrounding communities are among the worst in the province. The rates for...
Read more...
All similar articles: 69 >>
cancer breast survival chemotherapy Birse radiation colon prostate rate Priamo rectum Hamilton
13 hrs ago | dailypress.com
Veteran credits Philadelphia treatment center for success beating prostate cancer When Floyd Walker, now 62, was diagnosed with prostate cancer five years ago, his treatment choices were limited, both by his health history and...
Read more...
Prue Salasky Walker Hampton cancer 5-year CTCA celebrate Philadelphia Treatment prostate Centers hospital Floyd
17 hrs ago | wn.com
The outdated system was devised for glioblastoma and related brain tumors that were treated by radiation therapy only, and it relied on clinical signs and symptoms. It divided patients into six prognostic groups. The new system...
Read more...
All similar articles: 200 >>
glioblastoma identifiable wn.com email newsletter personally patient disclose prostate inquiry cancer Privacy collect address receive personal Policy
19 hrs ago | finanznachrichten.de
May 16, 2012--Dendreon Corporation (NASDAQ:DNDN) today announced the following PROVENGE® (sipuleucel-T) data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting American Society of Clinical...
Read more...
PROVENGE Dendreon Sipuleucel-T patient prostate PSA baseline infusion Cancer treatment
19 hrs ago | eurekalert.org
Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary...
Read more...
prostate Cu-64 imaging Jefferson noninvasive NIH cancer Thakur VPAC1 biopsy study method grant tumor biomarker
20 hrs ago | stuff.co.nz
BRIGHTER DAY: Totara Hospice South Auckland community nurse Gwen Singer shares a laugh with blind cancer sufferer Enesi Puni. Debilitating illness and treatment can take the joy out of living. But weekly visits from a...
Read more...
Puni hospice Enesi Auckland Totara nurse prostate Singer cancer palliative Mr Gwen
May 16, 2012 | telegraph.co.uk
For men who believe that they have a raw deal when it comes to funding research and treatment for prostate cancer, the U-turn by NICE over its original non-recommendation of Abiraterone for advanced stages of the disease must...
Read more...
NICE Abiraterone Cabazitaxel drug U-turn prostate cancer
May 16, 2012 | finanznachrichten.de
Not intended for US media Oslo, Norway, 16 May 2012 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that further data from the phase III ALSYMPCA study of...
Read more...
Thomson Alpharadin Algeta radium-223 chloride ALSYMPCA ASA metastasis phase III
May 16, 2012 | walesonline.co.uk
Nearly 37,000 men are diagnosed with prostate cancer every year but many symptoms can be put down to other conditions. Julia McWatt talks to two men – Jeff Pritchard and Jeff Sainsbury – on living with the disease
Read more...
prostate cancer PSA Jeff Cardiff pain doctor biopsy level
May 16, 2012 | fortmilltimes.com
Revenue increases 115% over first Quarter 2011 IRVINE, Calif. & LIEGE, Belgium -- Regulatory News: MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to...
Read more...
MDxHealth ConfirmMDx Prostate Pharmaco Q1 Cancer Diagnostics test revenue
May 16, 2012 | reuters.com
that was developed in the country after maker Johnson & Johnson agreed a new discount on supplies to the UK state healthcare service. Zytiga, which is known chemically as abiraterone,... In this article: Britain , Johnson &...
Read more...
prostate U-turn cancer pill drug Britain abiraterone fund NICE Janssen Research patient Institute
May 16, 2012 | wiley.com
What's known on the subject? and What does the study add?Diethylstilbestrol (DES) has been found to have anti‐tumour properties and clinical effectiveness in prostate cancer that is resistant to the first‐line hormonal...
Read more...
Pierre-Olivier Bosset diethylstilbestrol DES prostate CRPC cancer advanced anti-tumour BJU role therapy clinical management
May 16, 2012 | libdemblogs.co.uk
John Leech MP and Owen Sharp, Chief Executive of Prostate Cancer Charity Chorlton MP John Leech has spoken of his delight that the prostate cancer drug 'abiraterone' has been approved today for use on the NHS in England and...
Read more...
Prostate Leech Cancer NHS NICE drug Charity Chorlton MP
May 15, 2012 | reuters.com
LONDON, May 16 (Reuters) - Britain's drug watchdog has reversed a controversial decision not to fund a new prostate cancer pill that was developed in the country after maker Johnson & Johnson agreed a new discount on supplies...
Read more...
prostate U-turn cancer pill drug Britain abiraterone fund NICE Janssen Research patient
May 15, 2012 | bio-medicine.org
DETROIT Black prostate cancer patients may not be getting the same quality of care as white patients, according to a first-of-its-kind study by researchers at Henry Ford Hospital who found racial disparities in the results of...
Read more...
prostate surgery patient cancer Trinh care quality disparity bad result African anatomical study difference Quoc-Dien American Vattikuti
May 15, 2012 | tmcnet.com
Overview We are a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. We operate primarily in the emerging field of...
Read more...
NeoGenomics SVM Retinalyze Company 2012 patent 31 analysis EYEPA
May 15, 2012 | naplesnews.com
21st Century Oncology, in partnership with the Southwest Florida Hispanic Chamber of Commerce, is hosting a free health seminar on breast and prostate cancer Thursday, May 24 from 3:00 until 5:00 p.m. at the Microtel Inn and...
Read more...
prostate seminar cancer breast Microtel health 239-418-1441 Acres free Lehigh 33936 Naples reservation
May 15, 2012 | seekingalpha.com
By Chemistfrog : With each era of discovery it seems there is always a leader with the innovative foresight and fortitude to lead a revolution and conquer a foe. The tools used to defeat the enemy are considered to be marvels...
Read more...
Chemistfrog NeuVax Provenge cancer patient HER2 Dendreon Phase immunotherapy breast
May 15, 2012 | seekingalpha.com
By Theodore Cohen: The 2012 Annual Meeting of the American Urological Association, dubbed AUA2012, kicks of May 19 in Atlanta, GA, at the Georgia World Congress Center. Running through May 23, the meeting features more than 100...
Read more...
Theodore Cohen AUA2012 APC8015F Provenge sipuleucel-T survival Dendreon IMPACT DNDN AA hazard prostate trial African Frovenge placebo
May 15, 2012 | finanznachrichten.de
LAUSANNE and VILLARS-SUR-GLÂNE, Switzerland, May 15, 2012 /PRNewswire/ -- Debiopharm Group™ (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and commercialization in...
Read more...
Debiopharm Vifor Pamorelin Pharma formulation triptorelin Debio LA Salvacyl R.P.
May 14, 2012 | rxpgnews.com
An over-the-counter natural remedy derived from honeybee hives arrests the growth of prostate cancer cells and tumors in mice, according to a new paper from researchers at the University of Chicago Medicine. Caffeic acid...
Read more...
prostate micro-western CAPE cancer tumor protein blot treatment cell proteomics researcher compound hive remedy array
